Abstract
Alzheimer's disease and related dementias (AD/ADRD) affects more than 50 million people worldwide but there is no clear therapeutic option affordable for the general patient population. Recently, drug repositioning studies featuring collaborations between academic institutes, medical centers, and hospitals are generating novel therapeutics candidates against these devastating diseases and filling in an important area for healthcare that is poorly represented by pharmaceutical companies. Such drug repositioning studies converge expertise from bioinformatics, chemical informatics, medical informatics, artificial intelligence, high throughput and high-content screening and systems biology. They also take advantage of multi-scale, multi-modality datasets, ranging from transcriptomic and proteomic data, electronical medical records, and medical imaging to social media information of patient behaviors and emotions and epidemiology profiles of disease populations, in order to gain comprehensive understanding of disease mechanisms and drug effects. We proposed a recursive drug repositioning paradigm involving the iteration of three processing steps of modeling, prediction, and validation to identify known drugs and bioactive compounds for AD/ADRD. This recursive paradigm has the potential of quickly obtaining a panel of robust novel drug candidates for AD/ADRD and gaining in-depth understanding of disease mechanisms from those repositioned drug candidates, subsequently improving the success rate of predicting novel hits.